FyMed, Inc.

Press Releases
efficacy

FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B

Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...

FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract

Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...